Search

Meeting Program

All times are in GMT-3, local time in Brazil.

Read more

EHA Statement on COVID-19

The European Hematology Association (EHA) closely monitors the latest developments on the spreading of the Coronavirus (COVID-19).

Read more

Killer antibodies against AML

Most patients with acute myeloid leukemia (AML) can only be cured when a stem cell transplant induces an immune response against the patient’s leukemia.

Read more

Guidelines Committee

Current committee members
Carlo Dufour, Italy (Chair)
Martin Dreyling, Germany (Vice-Chair)
Steffen Koschmieder, Germany (Executive member)
Marieke Kruip, The Netherlands (Executive member)
Area associate members
Tamam Bakchoul, Germany
Sabine Blum, Switzerland 
Cristina Castilla Llorente, France 
Lydie Da Costa, France
Wojciech Jurczak, Poland
Noémi Roy, United Kingdom
Giovanna Russo, Italy
Cynthia So-Osman, The Netherlands
AimThe…

Read more

EHA-PTHiT Hematology Tutorial on Myeloid and Lymphoid Leukemias

Dates: September 21-22, 2018
Location: Warsaw, Poland
Chairs: T Robak,  G Gaidano, I Hus

Following successful previous editions, EHA is coordinating the third two-day tutorial in close collaboration with the Polish Society of Hematology and Transfusion Medicine on “Myeloid and Lymphoid Leukemias”.…

Read more

More than science: the European Affairs program at EHA2023

To develop and administer safe, innovative and effective treatments for patients with blood diseases, hematologists need an effective and enabling regulatory environment.

Read more

EHA Blood Cancer Awareness Month Wrap-up

The first European Hematology Association (EHA) Blood Cancer Awareness Month digital campaign aimed to raise awareness of hematological malignancies and EHA’s commitment “towards a cure for all blood disorders”.

Read more

About us

Welcome to the family! Get to know the Young EHA Committee and learn how you can make a difference. Join Young EHA through a junior membership. Meet the Young EHA committee members:

 
 
Name: Mandy N.

Read more

Major bleeding in patients on treatment with NOACs or VKAs in real-life: clinical presentation, management and outcome

Major bleeding in patients on treatment with NOACs or VKAs in real-life: clinical presentation, management and outcome

Limited data are available on major bleeding (MB) occurring during treatment with vitamin K (VKAs) or non-vitamin K antagonist oral anticoagulants (NOACs) outside clinical…

Read more